EXCALIBER-RRMM: This study is comparing the safety and effectiveness of two different drug combinations in people with relapsed or refractory multiple myelomaA Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)

Summary

This study has two stages.

In Stage One, participants will be randomly allocated to one of four treatment arms:

• Arm A1 will receive iberdomide in combination with daratumumab and dexamethasone (IberDd). In this arm, Iberdomide will be given at a dose of 1mg.
• Arm A2 will receive IderDd, where Ibderdomide will be given at a dose of 1.3mg.
• Arm A3 will receive IberDd, where Iberdomide will be given at a dose of 1.6mg.
• Arm B will receive daratumumab, bortezomib and dexamethasone (DVd).

In Stage Two, additional participants will be randomly allocated to one of two treatment arms:

• Treatment Arm A will receive IberDd
• Treatment Arm B will receive DVd

Dexamethasone and Iberdomide will be administered orally, while Daratumumanb and Bortezomib will be given as a subcutaneous injections.

Conditions

This trial is treating patients with relapsed or refractory multiple myeloma

More information